LDS/Medical Tests/Cytology, Non-gynecologic

Cytology, Non-gynecologic

Non-gynecologic cytology involves the microscopic examination of cells obtained from body sites outside of the female genital tract. Specimens may be exfoliative, such as urine, sputum, serous effusions, cerebrospinal fluid, or brushings, or obtained through fine-needle aspiration (FNA) of organs including the thyroid, breast, lung, lymph nodes, liver, pancreas, and salivary glands. The primary objective of non-gynecologic cytology is to detect malignancy, while also identifying infectious, inflammatory, and benign reactive processes, using minimally invasive sampling techniques.

Specimen preparation is a critical determinant of diagnostic accuracy. Conventional smears involve direct placement of cellular material onto glass slides, which can result in air-drying artifact, variable thickness, and obscuring blood or mucus. Liquid-based preparations, including ThinPrep and SurePath, are increasingly used for both exfoliative specimens and FNA samples. These methods suspend cells in a preservative medium and process them using automated systems to produce a thin, uniform cellular layer. Liquid-based preparations improve specimen adequacy, background clarity, and slide consistency but introduce characteristic cytomorphologic alterations that must be recognized during interpretation.

Compared with conventional smears, liquid-based preparations typically show cleaner backgrounds due to removal of blood, mucus, necrosis, and inflammatory debris. Cells are evenly distributed within a defined area, improving screening efficiency and nuclear detail. However, processing may result in reduced cell and nuclear size, increased cellular discohesion, fragmentation of papillary structures, loss or alteration of extracellular material such as colloid or mucin, and reduced visualization of fibrovascular cores. Despite these changes, key architectural features including cellular clusters, sheets, and limited three-dimensionality are generally preserved.

In FNA specimens, liquid-based preparations maintain many diagnostic features but introduce specific pitfalls. Examples include diminished colloid in thyroid aspirates, reduced myxoid stroma in salivary gland pleomorphic adenomas, or altered nuclear molding in small cell carcinoma. Awareness of these preparation-related artifacts is essential to avoid diagnostic overinterpretation or undercalling. Overall, non-gynecologic cytology remains a cornerstone of diagnostic pathology, providing rapid, reliable, and minimally invasive evaluation. When combined with ancillary studies such as immunocytochemistry, molecular testing, and fluorescence in situ hybridization, cytology plays a central role in diagnosis, staging, and patient management across a wide range of diseases.

  • Primary distinction between benign/reactive processes and malignancy
  • Triage of specimens for ancillary testing including immunocytochemistry, flow cytometry, FISH, PCR, and next-generation sequencing
  • Detection and staging of metastatic disease in effusions or aspirates
A positive cytologic result indicating malignant cells generally requires confirmation with histologic tissue biopsy, as tissue architecture provides definitive diagnostic information. Histologic confirmation is recommended before initiating definitive or high-risk therapeutic interventions to ensure accurate diagnosis and appropriate treatment planning. Atypical or suspicious cytology results warrant further evaluation based on the degree of cytologic abnormality and clinical context. This may include repeat cytologic sampling, close clinical follow-up, ancillary testing, or tissue biopsy to clarify the nature of the findings.

Negative for malignant cells

CytoSpin or liquid-based preparation (ThinPrep or SurePath) with Papanicolaou staining.

Preservative when liquid-based preparation is requested (e.g., PreservCyt for ThinPrep, CytoRich for SurePath).

Transport at room temperature unless otherwise specified.

Specimens intended for flow cytometry or cytogenetic analysis should be submitted unfixed in an appropriate balanced medium.

Cell block preparation with immunocytochemistry for lineage or tumor markers, FISH assays such as UroVysion for urine specimens, PCR or next-generation sequencing panels for actionable mutations, and microbiologic stains or cultures when infection is suspected.
2 to 5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login